PARIS, Dec. 7, 2010 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia) for access to its fluorescent proteins. This license allows Cellectis bioresearch to incorporate these proteins into its own products and will expand the company's offering of genome engineering tools.
Luc Selig, Sales and Marketing Director of Cellectis bioresearch, commented, "One of the key components of our kits is the integration matrix which enables the user to express a gene of interest. By extending the choice of promoters and tags in these matrices, we can offer our clients a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."
Cellectis bioresearch develops and commercializes ready- and easy-to-use tools and technologies for the life science industry. These tools can be used to customize any cell for drug development, protein production or functional genomics. To date, Cellectis bioresearch markets over one hundred products through its online store and international distribution network and sales forces.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The kits can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors
|SOURCE Cellectis bioresearch|
Copyright©2010 PR Newswire.
All rights reserved